Skip to main content

Human Organoids Expose Limits of Pancreatic Cancer Mouse Models

A new stem-cell-derived model suggests human pancreatic cells require multiple genetic failures before becoming cancerous and lose key identity programs as tumors emerge.

Written byAnirban Mukhopadhyay, PhD
| 3 min read
A 3D digital illustration depicting a tumor growing on the human pancreas.
Register for free to listen to this article
Listen with Speechify
0:00
3:00

Scientists still do not fully understand how human pancreatic cells first become cancerous, limiting efforts to identify the disease at its earliest stages.

“Early detection of pancreatic cancer is mostly missed because in 80 percent of cases, the tumor becomes symptomatic only after it has progressed to advanced stages,” said Jaskaran Singh Sethi, a radiation oncologist at Rajiv Gandhi Cancer Institute and Research Center, who was not involved in the study.

Together, these challenges have made it difficult to identify early biomarkers or directly study the molecular events that initiate malignant transformation.1

In a new study published in Developmental Cell, researchers developed human pancreatic organoids that reproduced the earliest stages of pancreatic ductal adenocarcinoma (PDAC) development and found that, unlike in many mouse models, activating the cancer-driving gene Kirsten rat sarcoma virus oncogene homologue (KRAS) alone was insufficient to drive tumor formation.2

Instead, the human cells remained resistant unless multiple tumor-suppressive barriers were disrupted, suggesting that early pancreatic tumorigenesis in humans may be more complex than existing animal models have captured. The system also modeled progression toward aggressive forms of PDAC, potentially providing a platform to study early biomarkers and mechanisms of disease progression.

For decades, genetically engineered mouse models have served as the dominant experimental system for studying pancreatic cancer initiation, helping establish oncogenic KRAS as a central driver of PDAC development.3 However, increasing evidence suggested that malignant transformation in human pancreatic cells may require overcoming multiple tumor-suppressive barriers not fully captured in many mouse models.4

Continue reading below...

Like this story? Sign up for FREE Cancer updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

The question naturally arose: Which cellular states should scientists study to capture the early footprints of PDAC in humans?

Previous work suggested that pancreatic injury and inflammation can trigger acinar-to-ductal metaplasia (ADM), a regenerative reprogramming process in which mature pancreatic cells adopt a more plastic, progenitor-like state that may become permissive for tumor initiation.5

To model this vulnerable state in a human system, researchers at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine developed pancreatic organoids from human pluripotent stem cells. The organoids retained embryonic pancreatic progenitor features while also recapitulating molecular characteristics associated with inflamed pancreatic epithelium and ADM.

Using this system, the researchers systematically introduced combinations of mutations commonly found in PDAC to test which genetic alterations were required for transformation.

The researchers found that combining KRAS activation with loss of either the tumor suppressor genes cyclin-dependent kinase inhibitor 2A (CDKN2A) or tumor protein p53 (TP53) still failed to produce tumors after transplantation into mice. However, organoids carrying KRAS activation together with loss of both CDKN2A and TP53 consistently formed pancreatic precursor lesions and moderately differentiated PDAC after transplantation.

In particular, CDKN2A loss appeared necessary for KRAS- and TP53-driven transformation, indicating that human pancreatic cells may possess stronger safeguards against malignant progression than traditional mouse systems have fully captured.

An additional loss of SMAD family member 4 (SMAD4) also drove progression toward a more aggressive, poorly differentiated, basal-like disease state associated with poorer clinical outcomes, suggesting that the organoid system can capture not only early tumor initiation, but also the emergence of clinically aggressive pancreatic cancer.6

The researchers then examined how the organoids changed during malignant progression to better characterize the early molecular landscape of pancreatic tumorigenesis.

They found that this transition involved two parallel shifts: activator protein 1 (AP-1) transcription factors appeared to drive the oncogenic side of this transition, promoting activation of malignant PDAC programs. At the same time, declining expression of ten-eleven translocation methylcytosine dioxygenase 1 (TET1) weakened molecular programs linked to pancreatic lineage identity. The researchers traced both processes to ERK signaling activated by mutant KRAS, suggesting that the same pathway may simultaneously promote cancer-driving programs while dismantling mechanisms that preserve normal cellular identity.

Together, the findings suggest that early pancreatic tumorigenesis may involve not only accumulation of oncogenic mutations, but also progressive erosion of the molecular features that maintain normal pancreatic identity.

By modeling the earliest stages of human pancreatic cancer development, Sethi said, this “important study identifies key molecular and epigenetic events driving [malignant] transformation.”

Such work has the potential to aid early detection, risk prediction, and development of preventive or targeted therapies, he said.

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Anirban Mukhopadhyay wears a jacket against a snowy background.

    Anirban Mukhopadhyay is an independent science journalist based in India with a PhD in genetics from Delhi University. He reports regularly for The Hindu, where he conveys complex biomedical research to the public in an accessible language. His work has also appeared in Live Science, C&EN, and The Wire Science where he explores how multidisciplinary research intersects with society. Find him on X @onipedia.

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation